louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03337295: The Correlation Between the Thickness of Lipid Layer and the Meibomian Gland Dysfunction
Official title: The Correlation Between the Thickness of Lipid Layer and the Meibomian Gland
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Meibomian Gland Dysfunction
Keywords: Meibomian Gland Dysfunction
Lipid Layer Thickness
Lead sponsor: Wenzhou Medical University
Sponsor class: OTHER
First posted: 2017-11-08
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study was consisted of patients who underwent the Meibomian Gland Dysfunction through the signs. The Office of Research Ethics,Eye Hospital of Wenzhou Medical University approved the study protocol, and all patients provided their informed consent.

Brief summary: The purpose of this study is to assess the correlation between the thickness of lipid layer and the meibomian gland dysfunction.


Eligibility criteria: Inclusion Criteria:

* Patients who underwent the Meibomian Gland Dysfunction through the signs.

Exclusion Criteria:

* Eye surgery history

Primary outcomes:
measure: Lipid Layer Thickness
timeFrame: up to 2 years
Secondary outcomes:
measure: Atrophy of Meibomian Gland
timeFrame: up to 2 years
Other outcomes:
Locations:
city: Wenzhou
country: China
facility: Wenzhou Medical University
state: Zhejiang
Study officials:
affiliation: Wenzhou Medical University
name: Yun-e Zhao, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00543595: MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetes Mellitus, Type 2
Metabolic Syndrome
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2007-10-15
Enrollment: 154
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will test the safety and effectiveness of MK0916 in patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).


Eligibility criteria: Inclusion Criteria:

* Have Type 2 Diabetes
* 18 to 65 years of age

Exclusion Criteria:

* History of Type 1 Diabetes Mellitus
* Have been treated with insulin in the past 8 weeks
* On a weight loss program and have ongoing weight loss
* Taking weight loss medication
* Have had surgery requiring general anesthesia in the past 30 days or have a planned surgery
* Have taken another investigational drug in the last 8 weeks
* Have active liver disease
* Have a history of major surgery involving gastric or intestinal bypass

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Feig PU, Shah S, Hermanowski-Vosatka A, Plotkin D, Springer MS, Donahue S, Thach C, Klein EJ, Lai E, Kaufman KD. Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes Metab. 2011 Jun;13(6):498-504. doi: 10.1111/j.1463-1326.2011.01375.x.
Clinical trial NCT02089295: Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions
Official title: An Open-label, Randomized, Single-dose, Three-way Crossover Study to Evaluate the Dose Proportionality of 5 Mg, 20 Mg and 40 Mg of PF-00345439 Formulation K Under Intermediate-fat Fed Conditions in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: dose proportionality
oxycodone
Lead sponsor: PainT
Sponsor class: UNKNOWN
First posted: 2014-03-17
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: To evaluate the dose proportionality of 5 mg, 20 mg and 40 mg of PF 00345439 formulation under fed conditions in healthy volunteers.


Eligibility criteria: Inclusion Criteria:

* Healthy male and/or female subjects between 18 and 55 years of age

Exclusion Criteria:

* Evidence or history of clinically significant disease.
* Positive urine drug test

Primary outcomes:
measure: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
measure: Maximum Observed Plasma Concentration (Cmax)
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
Secondary outcomes:
measure: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
measure: Concentration at time 24 hours (C24)
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
measure: Time to Reach Maximum Observed Plasma Concentration (Tmax)
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
measure: Plasma Decay Half-Life (t1/2)
timeFrame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48
Other outcomes:
Locations:
city: Overland Park
country: United States
facility: Pfizer Investigational Site
state: Kansas
city: Overland Park
country: United States
facility: Pfizer Investigational Site
state: Kansas
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00126295: Evaluation of an Individualised Written Education Package for Stroke Patients
Official title: Evaluation of a Computer-Generated Individualised Written Education Package for Patients Following Stroke and Their Carers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Stroke
Lead sponsor: Medical Benefits Fund of Australia
Sponsor class: INDUSTRY
First posted: 2005-08-03
Enrollment: 130
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: ECT

Brief summary: The primary aim of the randomised controlled trial was to evaluate the effectiveness of a tailored written education package ("What you need to know about stroke") on the outcomes of:

* Knowledge about stroke, self-efficacy, anxiety, depression, perceived health status, satisfaction with the content and presentation of the information received, and desire for additional information for patients following stroke and
* Knowledge about stroke, self-efficacy, anxiety, depression, satisfaction with the content and presentation of the information received, and desire for additional information for their carers.

A secondary aim was to evaluate the effect of written information on the outcomes of knowledge about stroke, self-efficacy, anxiety, depression, and perceived health status of patients following stroke and on knowledge about stroke, self-efficacy, anxiety, and depression of their carers.


Eligibility criteria: Inclusion Criteria:

* Had a stroke or transient ischemic attack (TIA) or was the informal carer of a person who had a stroke or TIA;
* Had a reported English-proficiency level, corrected hearing and vision, and communication status adequate to participate in an interview and complete assessment tasks;
* Did not have reported or observable dementia;
* Lived within 50km of the hospital, for ease of follow-up; and
* Was medically stable.

Primary outcomes:
measure: knowledge about stroke
measure: self-efficacy
measure: anxiety
measure: depression
measure: perceived health status (patients only)
measure: satisfaction with the content and presentation of the information received
measure: desire for additional information
Secondary outcomes:
Other outcomes:
Locations:
city: Brisbane
country: Australia
facility: Royal Brisbane Hospital
state: Queensland
Study officials:
affiliation: The University of Queensland
name: Tammy C Hoffmann
role: PRINCIPAL_INVESTIGATOR
affiliation: The University of Queensland
name: Kryss McKenna
role: PRINCIPAL_INVESTIGATOR
affiliation: The University of Queensland
name: Linda Worrall
role: PRINCIPAL_INVESTIGATOR
affiliation: Royal Brisbane Hospital
name: Stephen Read
role: PRINCIPAL_INVESTIGATOR
References:
citation: Crocker TF, Brown L, Lam N, Wray F, Knapp P, Forster A. Information provision for stroke survivors and their carers. Cochrane Database Syst Rev. 2021 Nov 23;11(11):CD001919. doi: 10.1002/14651858.CD001919.pub4.
Clinical trial NCT06098495: Looking for a Blood Epigenetic Signature to Predict Female Infertility
Official title: Looking for a Blood Epigenetic Signature to Predict Female Infertility
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Female Infertility
Lead sponsor: Università Vita-Salute San Raffaele
Sponsor class: OTHER
First posted: 2023-10-24
Enrollment: 1456
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 43
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Infertile woman undergoing ART, women affected by recurrent pregnancy loss, women attempting to conceive naturally

Brief summary: The present research project aims to study the DNAm mechanisms underlying the reduction of fertility due to the progressive depletion of oocyte quality. Specifically, our project aims to build an epigenetic clock for MGCs by using outcomes that are certainly related to female fertility. The validation of such findings will be carried out on peripheral blood in order to guarantee its non-invasiveness and allow for any clinical transferability. In order to identify a blood epigenetic signature able to predict female infertility, we planned to explore the problem from different points of view by conducting several studies in different settings.


Eligibility criteria: Inclusion Criteria:

* 18\< age \<43, Infertile woman undergoing ART, recurrent pregnancy loss

Exclusion Criteria:

* age \< 18 or \> 44, previous ovarian surgery, severe male factor infertility

Primary outcomes:
measure: differences of DNA methylation in granulosa cells of patients undergoing ART
timeFrame: 3 years
measure: differences of DNA methylationin the peripheral venous blood of patients undergoing ART
timeFrame: 3 years
measure: differences of DNA methylationin the peripheral venous blood of women attempting to conceive naturally
timeFrame: 3 years
measure: differences of DNA methylationin the peripheral venous blood of new patients undergoing ART
timeFrame: 3 years
measure: impact of exogenous pro-inflammatory factors
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Università Vita Salute San Raffaele
Study officials:
References:
Clinical trial NCT02832895: Frontal Bone Window in ICUF (FBW-ICU)
Official title: Assessment of Frontal Bone Window for Transcranial Doppler Among Acute Brain Injured Patients in Intensive Care Units: a Prospective Study.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Acute Brain Injury
Keywords: Adults
Frontal bone window
Transcranial doppler
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2016-07-14
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Transcranial doppler (TCD) is an established tool for monitoring flows in intracranial cerebral arteries. Its use is recommanded in the last guidelines on traumatic brain injury. The temporal bone window (TBW) is limited in evaluating flow in the anterior cerebral arteries (ACA) because of an unfavorable insonation angle. Thereby TCD could be unfit to detect a segmental lesion on the anterior cerebral arteries (ACA).

The frontal bone window (FBW) is a promising approach in evaluating flows in the ACA. However, the utility of the FBW for patients with acute brain injury (ABI) in ICU has not been yet determined.

The goal of the present study is to determine the rate of detection of the ACA by using the FBW in patients with ABI in ICU.


Eligibility criteria: Inclusion Criteria:

* Membership in a health insurance scheme
* Patients with an acute cerebral pathology
* Hospitalized patients in a supportive care unit of Montpellier University Hospital
* Be able to benefit from transcranial doppler within 3 days of admission

Exclusion Criteria:

* Clinical suspicion of encephalic death
* Known allergy to ultrasound gel

Primary outcomes:
measure: measures of ACA flow velocities threw the frontal bone window
timeFrame: up to 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Montpellier University Hospital
Study officials:
affiliation: Montpellier University Hospital
name: Camille CM Maury, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01760395: Complications in Inguinal Hernia Surgery
Official title: Complications in Inguinal Hernia Surgery - a Nationwide Registry Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Inguinal Hernia
Lead sponsor: North Karelia Central Hospital
Sponsor class: OTHER
First posted: 2013-01-04
Enrollment: 335
Sex: ALL
Minimum age (years): 16
Maximum age (years): 110
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Finnish patients having had complicated inguinal hernia surgery 2002-2010.

Brief summary: Inguinal hernia repair is the most common procedure in general surgery. Even with acceptable complication rates, thousands of patients worldwide suffer from inguinal hernia surgery complications every year. In Finland, the Finnish Patient Insurance Centre (FPIC) receives reports from surgical complications. In this study, the database of FPIC is used to compare the complication profiles of open and laparoscopic inguinal hernia surgery with mesh.


Eligibility criteria: Inclusion Criteria:

* surgery between 2002 and 2010
* complicated inguinal hernia surgery reported to FPIC

Exclusion Criteria:

* none

Primary outcomes:
measure: surgical complication
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Kouhia S, Vironen J, Hakala T, Paajanen H. Open Mesh Repair for Inguinal Hernia is Safer than Laparoscopic Repair or Open Non-mesh Repair: A Nationwide Registry Study of Complications. World J Surg. 2015 Aug;39(8):1878-84; discussion 1885-6. doi: 10.1007/s00268-015-3028-2.
Clinical trial NCT01276795: Whey Protein-based Enteral Nutrition Support to Improve Protein Economy in Surgical Patients
Official title: Whey Protein-based Enteral Nutrition Support to Improve Protein Economy in Surgical Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Protein Metabolism
Colorectal Neoplasms
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor class: OTHER
Collaborators: name: McGill University
First posted: 2011-01-13
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: A prospective, randomized and controlled study is proposed to establish whether an enteral nutrition support regimen based on pressurized whey protein and glucose improves the postoperative utilization of amino acid substrates compared to a drink based on glucose alone. The kinetics of protein metabolism (protein breakdown, protein synthesis and amino acid oxidation) will be investigated using stable isotope methodology before and after surgery in patients undergoing colon resection. Stable isotope infusions will be conducted one week before surgery and on the second postoperative day for two hours in the fasted state and for four hours while sipping the enteral nutrition support regimen. Patients will consume one of two enteral nutrition support regimens consisting of a drink containing either pressurized whey protein and glucose or glucose alone. It is hypothesized that an enteral nutrition support regimen based on pressurized whey protein and glucose promotes positive protein balance through increased protein synthesis or reduced protein breakdown compared to glucose alone.


Eligibility criteria: Inclusion Criteria:

* age older than 18 years
* ASA class I to III
* colorectal surgery for non-metastatic disease (including right, transverse, left, sigmoid, subtotal, total and hemicolectomy and low anterior resection)
* body mass index \>17 and \<30 kg.m-2
* stable weight over the preceding three months (\<10 % body weight loss)
* serum albumin \>35 g/L

Exclusion Criteria:

* severe cardiac, renal or hepatic failure
* diabetes
* hyper and hypothyroidism
* active inflammatory bowel or diverticular disease
* musculoskeletal or neuromuscular disease
* anemia (hematocrit \<30)
* albumin \< 25 g/l
* pregnancy
* use of steroids.

Primary outcomes:
measure: Protein balance
timeFrame: Assessed for 6 hours one time before surgery and once again on the second post-op day
Secondary outcomes:
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Montreal General Hospital
state: Quebec
Study officials:
affiliation: McGill University
name: Franco Carli, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06974695: Identification of Predictive Factors for Failure of Cholangioscopy-assisted Lithotripsy in the Management of Complex Bile Duct Stones: a Retrospective Study
Official title: Predictive Factors for Cholangioscopy-Assisted Lithotripsy Failure in the Management of Complex Biliary Stones: A Retrospective Analysis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Bile Duct Stones
Keywords: Cholangioscopy
Spyglass
Failure
Complex bile duct stone
predictive factor
electrohydraulic lithotripsy
EHL
lithotripsy
ERCP
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2025-05-16
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any adult patient who underwent cholangioscopy-guided lithotripsy for bile duct stones between January 1, 2018, and May 30, 2025

Brief summary: This study aims to optimize the management of complex biliary stones by identifying predictive factors for SpyGlass lithotripsy failure.


Eligibility criteria: Inclusion Criteria:

* Any adult patient who underwent cholangioscopy-guided lithotripsy for bile duct stones between January 1, 2018, and May 30, 2025

Exclusion Criteria:

* Patient who objected to the collection of their data

Primary outcomes:
measure: Predictive factors for failure of cholangioscopy lithotripsy in the management of complex bile duct stone
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Vandœuvre-lès-Nancy
country: France
facility: CHRU Brabois Vandoeuvre les Nancy
state: Lorraine
Study officials:
name: Marion SCHAEFER, hospital practitioner
role: STUDY_DIRECTOR
References:
Clinical trial NCT04888195: Symptom Clusters in Hong Kong Chinese Children With Blood Cancer
Official title: Symptom Clusters in Hong Kong Chinese Children With Blood Cancer:: A Longitudinal Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Child
Keywords: blood cancer
chemotherapy
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
First posted: 2021-05-17
Enrollment: 120
Sex: ALL
Minimum age (years): 5
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We will recruit pediatric patients with blood cancer in the Hong Kong Children's Hospital

Brief summary: Pediatric blood cancer is the most common childhood malignancy. Despite its survival has been substantially improved, children still have to pay a high price for numerous distressing symptoms resulted from chemotherapy. Previous studies related to symptom experiences mainly focus on individual symptoms, rather than on multiple symptoms. Understanding these distressing symptoms may help healthcare professionals to develop appropriate and effective interventions with the aims of alleviating symptom severity and thus promoting the child's psychosocial well-being and quality of life.

Detailed description: A longitudinal study design will be conducted. A sample of 120 patients age 5-17years, diagnosed with blood cancer but not yet receive any chemotherapy and able to communicate with Cantonese and read Chinese will be recruited in the pediatric oncology ward of Hong Kong Children's Hospital.

Eligibility criteria: Inclusion Criteria:

* aged 5 - 17 years old
* diagnosed with blood cancer but not yet receive any chemotherapy
* able to communicate with Cantonese and read Chinese

Exclusion Criteria:

* who are scheduled to have concurrent cancer treatment
* with recurrent malignancy
* medical condition, or cognitive and learning problems in their medical records

Primary outcomes:
measure: The therapy-related symptom checklist for children (TRSC-C)
timeFrame: Before chemotherapy
measure: The therapy-related symptom checklist for children (TRSC-C) at 1-week
timeFrame: At 1-week follow-up
measure: The therapy-related symptom checklist for children (TRSC-C) at 1-month
timeFrame: At 1-month follow-up
measure: The therapy-related symptom checklist for children (TRSC-C) at 3-month
timeFrame: At 3-month follow-up
measure: The therapy-related symptom checklist for children (TRSC-C) at 6-month
timeFrame: At 6-month follow-up
measure: Demographic sheet
timeFrame: At baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Ka Yan Ho
state: Hong Kong,China
Study officials:
affiliation: The Hong Kong Polytechnic University
name: Ka Yan Ho, PhD
role: PRINCIPAL_INVESTIGATOR
References: